13 results on '"Nori, Achyuta V"'
Search Results
2. Genomic epidemiology of syphilis reveals independent emergence of macrolide resistance across multiple circulating lineages
- Author
-
Beale, Mathew A., Marks, Michael, Sahi, Sharon K., Tantalo, Lauren C., Nori, Achyuta V., French, Patrick, Lukehart, Sheila A., Marra, Christina M., and Thomson, Nicholas R.
- Published
- 2019
- Full Text
- View/download PDF
3. Self-start HIV postexposure prophylaxis (PEPSE), to reduce time to first dose and increase efficacy.
- Author
-
Fox, Julie M., Ming Jie Lee, Leach Fairhead, Cassandra, Ledwaba-Chapman, Lesedi m., Nori, Achyuta V., McQuillan, Orla, Yanzhong Wang, Clarke, Amanda, and Menon-Johansson, Anatole
- Published
- 2023
- Full Text
- View/download PDF
4. High Prevalence of Antibiotic-Resistant Mycoplasma genitalium in Nongonococcal Urethritis: The Need for Routine Testing and the Inadequacy of Current Treatment Options
- Author
-
Pond, Marcus J., Nori, Achyuta V., Witney, Adam A., Lopeman, Rose C., Butcher, Philip D., and Sadiq, Syed Tariq
- Published
- 2014
- Full Text
- View/download PDF
5. Impact of deploying multiple point-of-care tests with a ‘sample first’ approach on a sexual health clinical care pathway. A service evaluation
- Author
-
Harding-Esch, Emma M, Nori, Achyuta V, Hegazi, Aseel, Pond, Marcus J, Okolo, Olanike, Nardone, Anthony, Lowndes, Catherine M, Hay, Phillip, and Sadiq, S Tariq
- Published
- 2017
- Full Text
- View/download PDF
6. Performance evaluation of automated urine microscopy as a rapid, non-invasive approach for the diagnosis of non-gonococcal urethritis
- Author
-
Pond, Marcus J, Nori, Achyuta V, Patel, Sheel, Laing, Ken, Ajayi, Margarita, Copas, Andrew J, Butcher, Philip D, Hay, Phillip, and Sadiq, Syed Tariq
- Published
- 2015
- Full Text
- View/download PDF
7. An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy.
- Author
-
Alagaratnam, Jasmini, Peters, Helen, Francis, Kate, Kay, Natasha, Gilleece, Yvonne, Finnerty, Fionnuala P., Grimes, Rosanna E., Parry, Sarah, Portman, Mags, Wait, Brenton C., Shah, Rimi, Roedling, Sherie, Hawkins, David A., Chitty, Sarah, Sarner, Liat, Marcus, Rebecca, Hartley, Anna, Nori, Achyuta V., Rosenvinge, Melanie, and Taylor, Graham P.
- Subjects
THERAPEUTIC use of protease inhibitors ,DELIVERY (Obstetrics) ,GESTATIONAL age ,HIV infections ,MEDICAL cooperation ,SCIENTIFIC observation ,REGRESSION analysis ,RESEARCH ,RNA ,VIRAL load ,HIGHLY active antiretroviral therapy ,TREATMENT effectiveness ,RETROSPECTIVE studies ,HIV integrase inhibitors ,NON-nucleoside reverse transcriptase inhibitors - Abstract
Background: In pregnancy, reduction of HIV plasma viral load (pVL) for the prevention of vertical transmission is time-constrained. The study primary objective is to investigate factors associated with faster initial HIV RNA half-life decay when combination antiretroviral treatment (cART) is initiated in pregnancy. Methods: This was a multicentre, retrospective, observational study, conducted in south England, United Kingdom, between August 2001 and February 2018. Data were extracted from case notes of eligible women initiating cART during the index pregnancy. Anonymised data were collated and analysed centrally. Regression analyses were conducted to determine factors associated with faster HIV RNA half-life decay in the first 14 days after commencing cART (first-phase), and with achieving an undetectable maternal pVL by 36 weeks' gestation. We then assessed whether HIV- and obstetric- related parameters differed by antiretroviral third agent class and whether the proportions of women with undetectable pVL at 36 weeks' gestation and at delivery differed by antiretroviral third agent class. Results: Baseline pVL was the only independent factor associated with faster first-phase HIV RNA half-life decay on commencing cART. Lower pVL on day 14 after starting cART was associated with an increased likelihood of achieving an undetectable pVL by 36 weeks' gestation. Integrase inhibitor-based cART was associated with a faster first-phase HIV RNA half-life decay on commencing cART. Overall, 73% and 85% of women had an undetectable pVL at 36 weeks' gestation and at delivery respectively, with no significant difference by antiretroviral third agent class. Conclusions: Only high baseline pVL independently contributed to a faster rate of first-phase viral half-life decay. pVL at 14 days after initiating cART allows early identification of treatment failure. In the first 14 days after initiating cART in pregnancy, integrase inhibitor-based cART reduced maternal pVL faster than protease inhibitor- and non-nucleoside reverse transcriptase-based cART. While our study findings support INSTI use when initiated in pregnancy especially when initiated at later gestations and in those with higher baseline pVL, other non-INSTI based cART with more data on safety in pregnancy also performed well. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Impact of mass drug administration of azithromycin for trachoma elimination on prevalence and azithromycin resistance of genital infection.
- Author
-
Harrison, Mark Andrew, Harding-Esch, Emma Michele, Marks, Michael, Pond, Marcus James, Butcher, Robert, Solomon, Anthony W., Liqing Zhou, NgeeKeong Tan, Nori, Achyuta V., Kako, Henry, Sokana, Oliver, Mabey, David C. W., Sadiq, Syed Tariq, Zhou, Liqing, and Tan, NgeeKeong
- Abstract
Background: Mass drug administration (MDA) of 20 mg/kg (maximum 1 g in adults) azithromycin for ocular Chlamydia trachomatis (CT) infection is a key component of the WHO trachoma elimination strategy. However, this dose may be suboptimal in Mycoplasma genitalium infection and may encourage emergence of antimicrobial resistance (AMR) to azithromycin.Objectives: To determine the effect of MDA for trachoma elimination on M. genitalium prevalence, strain type and azithromycin resistance.Methods: A secondary analysis of CT-negative vulvovaginal swabs from three outpatient antenatal clinics (Honiara, Solomon Islands) from patients recruited either pre-MDA, or 10 months post-MDA in two cross-sectional surveys was carried out. Swabs were tested for M. genitalium infection using Fast Track Diagnostics Urethritis Plus nucleic acid amplification assay. M. genitalium-positive samples were subsequently tested for azithromycin resistance by sequencing domain V of the 23S rRNA DNA region of M. genitalium and underwent phylogenetic analysis by dual locus sequence typing.Results: M. genitalium prevalence was 11.9% (28/236) in women pre-MDA and 10.9% (28/256) 10 months post-MDA (p=0.7467). Self-reported receipt of azithromycin as part of MDA was 49.2% in women recruited post-MDA and 17.9% (5/28) in those who tested M. genitalium positive. Of samples sequenced (21/28 pre-MDA, 22/28 post-MDA), all showed a macrolide susceptible genotype. Strain typing showed that sequence types diverged into two lineages, with a suggestion of strain replacement post-MDA.Conclusion: A single round of azithromycin MDA in an island population with high baseline M. genitalium prevalence did not appear to impact on either prevalence or azithromycin resistance, in contrast to reported decreased genital CT prevalence in the same population. This may be due to limitations such as sample size, including CT-negative samples only, and low MDA coverage. Further investigation of the impact of multiple rounds of MDA on M. genitalium azithromycin AMR in antibiotic experienced and naïve populations is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. “It’s not a time spent issue, it’s a ‘what have you spent your time doing?’ issue…” A qualitative study of UK patient opinions and expectations for implementation of Point of Care Tests for sexually transmitted infections and antimicrobial resistance.
- Author
-
Fuller, Sebastian S., Pacho, Agata, Broad, Claire E., Nori, Achyuta V., Harding-Esch, Emma M., and Sadiq, Syed Tariq
- Subjects
SEXUALLY transmitted diseases ,QUALITATIVE research ,SOCIAL sciences ,SEMI-structured interviews ,EPIDEMIOLOGICAL models ,INFORMATION services - Abstract
Sexually transmitted infections (STIs) continue to be a major public health concern in the United Kingdom (UK). Epidemiological models have shown that narrowing the time between STI diagnosis and treatment may reduce the population burden of infection, and rapid, accurate point-of-care tests (POCTs) have potential for increasing correct treatment and mitigating the spread of antimicrobial resistance (AMR). We developed the Precise social science programme to incorporate clinician and patient opinions on potential designs and implementation of new POCTs for multiple STIs and AMR detection. We conducted qualitative research, consisting of informal interviews with clinicians and semi-structured in-depth interviews with patients, in six sexual health clinics in the UK. Interviews with clinicians focused on how the new POCTs would likely be implemented into clinical care; these new clinical pathways were then posed to patients in in-depth interviews. Patient interviews showed acceptability of POCTs, however, willingness to wait in clinic for test results depended on the context of patients’ sexual healthcare seeking. Patients reporting frequent healthcare visits often based their expectations and opinions of services and POCTs on previous visits. Patients’ suggestions for implementation of POCTs included provision of information on service changes and targeting tests to patients concerned they are infected. Our data suggests that patients may accept new POCT pathways if they are given information on these changes prior to attending services and to consider implementing POCTs among patients who are anxious about their infection status and/or who are experiencing symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Mpox in people with past infection or a complete vaccination course: a global case series.
- Author
-
Hazra, Aniruddha, Zucker, Jason, Bell, Elizabeth, Flores, John, Gordon, Leanna, Mitjà, Oriol, Suñer, Clara, Lemaignen, Adrien, Jamard, Simon, Nozza, Silvia, Nori, Achyuta V, Pérez-Barragán, Edgar, Rodríguez-Aldama, Juan Carlos, Blanco, Jose Louis, Delaugerre, Constance, Turner, Dan, Fuertes, Irene, Leiro, Viviana, Walmsley, Sharon L, and Orkin, Chloe M
- Subjects
- *
MONKEYPOX , *SEXUALLY transmitted diseases , *VACCINATION , *BISEXUAL men , *NATURAL immunity - Abstract
Since May, 2022, a large global outbreak of human mpox (formerly known as monkeypox) has predominantly affected men who have sex with men. The strain responsible, Clade IIb, has mutated substantially from precursors originating from the 2017–18 outbreak in Nigeria. Immunity to smallpox, another orthopoxvirus, via previous infection or vaccination provides lifelong immunity. However, since the 2022 mpox outbreak, recent clusters were described in individuals with presumed immunity through recent infection or vaccination. We aim to describe the epidemiological and clinical characteristics of mpox in individuals with past infection or vaccination to improve the understanding of this disease in the setting of previous immunity. In this global case series, international collaborators from nine countries provided data on individuals with PCR-confirmed mpox after documented previous infection or vaccination between May 11, 2022, and June 30, 2023. We excluded cases that could not confirm vaccination status or cases with partial immunisation or any doses received before the current multi-national mpox outbreak (cutoff date May 1, 2022). Data were collected via a case report spreadsheet that reported on dates of infection and vaccination, route of immunisation, demographic characteristics, clinical findings, HIV status, concomitant sexually transmitted infections, and markers of disease severity (mpox severity score system). We describe case epidemiology, clinical course, and mpox severity scores; all analyses were descriptive. We report mpox infections in 37 gay and bisexual men who have sex with men: seven individuals had mpox reinfections, 29 individuals had mpox infections that occurred after two appropriately spaced Modified Vaccinia Ankara-Bavarian Nordic vaccine courses, and one individual had an infection that met the criteria for both reinfection and infection after vaccination. The median age of individuals was 36 years (IQR 30–45; range 21–58). Those with natural immunity after initial infection had a shorter disease course with less mucosal disease upon reinfection than with their initial infection. Infections post-vaccination were characterised by few lesions, little mucosal disease, and minimal analgesia requirements; two people received oral tecovirimat. Overall, there were no deaths, no bacterial superinfections, and all individuals were managed in the ambulatory clinic with one hospital admission for a necrotising neck lesion. The epidemiology of people with mpox reinfection or infection post-vaccination was similar to other published cohorts during the 2022 outbreak—predominantly young, sexually active gay and bisexual men who have sex with men. Clinical features and outcomes of repeat infection and infection after vaccination appear to be less clinically severe than those described in 2022 case literature. Specifically, compared with the 2022 case series, these individuals in the present study had fewer confluent lesions, less mucosal involvement, reduced analgesia requirement, and fewer admissions. Natural immunity and vaccine-induced immunity are not fully protective against mpox infection. However, in this small series both disease duration and severity appear to be reduced. None. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Impact of mass drug administration of azithromycin for trachoma elimination on prevalence and azithromycin resistance of genital Mycoplasma genitalium infection.
- Author
-
Harrison MA, Harding-Esch EM, Marks M, Pond MJ, Butcher R, Solomon AW, Zhou L, Tan N, Nori AV, Kako H, Sokana O, Mabey DCW, and Sadiq ST
- Subjects
- Adolescent, Adult, Anti-Bacterial Agents administration & dosage, Azithromycin administration & dosage, Cluster Analysis, Cross-Sectional Studies, DNA, Bacterial chemistry, DNA, Bacterial genetics, DNA, Ribosomal chemistry, DNA, Ribosomal genetics, Female, Genotype, Humans, Melanesia epidemiology, Middle Aged, Molecular Typing, Mycoplasma Infections microbiology, Mycoplasma genitalium classification, Mycoplasma genitalium genetics, Mycoplasma genitalium isolation & purification, Phylogeny, Prevalence, RNA, Ribosomal, 23S genetics, Sequence Analysis, DNA, Trachoma prevention & control, Young Adult, Anti-Bacterial Agents adverse effects, Azithromycin adverse effects, Drug Resistance, Bacterial, Mass Drug Administration adverse effects, Mycoplasma Infections epidemiology, Mycoplasma genitalium drug effects, Trachoma drug therapy
- Abstract
Background: Mass drug administration (MDA) of 20 mg/kg (maximum 1 g in adults) azithromycin for ocular Chlamydia trachomatis (CT) infection is a key component of the WHO trachoma elimination strategy. However, this dose may be suboptimal in Mycoplasma genitalium infection and may encourage emergence of antimicrobial resistance (AMR) to azithromycin., Objectives: To determine the effect of MDA for trachoma elimination on M. genitalium prevalence, strain type and azithromycin resistance., Methods: A secondary analysis of CT-negative vulvovaginal swabs from three outpatient antenatal clinics (Honiara, Solomon Islands) from patients recruited either pre-MDA, or 10 months post-MDA in two cross-sectional surveys was carried out. Swabs were tested for M. genitalium infection using Fast Track Diagnostics Urethritis Plus nucleic acid amplification assay. M. genitalium -positive samples were subsequently tested for azithromycin resistance by sequencing domain V of the 23S rRNA DNA region of M. genitalium and underwent phylogenetic analysis by dual locus sequence typing., Results: M. genitalium prevalence was 11.9% (28/236) in women pre-MDA and 10.9% (28/256) 10 months post-MDA (p=0.7467). Self-reported receipt of azithromycin as part of MDA was 49.2% in women recruited post-MDA and 17.9% (5/28) in those who tested M. genitalium positive. Of samples sequenced (21/28 pre-MDA, 22/28 post-MDA), all showed a macrolide susceptible genotype. Strain typing showed that sequence types diverged into two lineages, with a suggestion of strain replacement post-MDA., Conclusion: A single round of azithromycin MDA in an island population with high baseline M. genitalium prevalence did not appear to impact on either prevalence or azithromycin resistance, in contrast to reported decreased genital CT prevalence in the same population. This may be due to limitations such as sample size, including CT-negative samples only, and low MDA coverage. Further investigation of the impact of multiple rounds of MDA on M. genitalium azithromycin AMR in antibiotic experienced and naïve populations is warranted., Competing Interests: Competing interests: MAH, EMHE and STS disclose having received funding outside the submitted work from Atlas Genetics, Alere, Cepheid, SpeeDx, Mologic and Sekisui. MJP discloses having received funding outside the submitted work from Atlas Genetics, Alere, Cepheid and Sekisui. AVN discloses having received funding outside the submitted work from Alere, Cepheid, SpeeDx and Sekisui. EMHE discloses their membership of the Becton Dickinson 'Provision of Sexual Health in the UK' advisory board. All other authors have nothing to disclose., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
12. 2016 United Kingdom national guideline on the sexual health care of men who have sex with men.
- Author
-
Clutterbuck D, Asboe D, Barber T, Emerson C, Field N, Gibson S, Hughes G, Jones R, Murchie M, Nori AV, Rayment M, and Sullivan A
- Abstract
This guideline is intended for use in UK Genitourinary medicine clinics and sexual health services but is likely to be of relevance in all sexual health settings, including general practice and Contraception and Sexual Health (CASH) services, where men who have sex with men (MSM) seek sexual health care or where addressing the sexual health needs of MSM may have public health benefits. For the purposes of this document, MSM includes all gay, bisexual and all other males who have sex with other males and both cis and trans men. This document does not provide guidance on the treatment of particular conditions where this is covered in other British Association for Sexual Health and HIV (BASHH) Guidelines but outlines best practice in multiple aspects of the sexual health care of MSM. Where prevention of sexually transmitted infections including HIV can be addressed as an integral part of clinical care, this is consistent with the concept of combination prevention and is included. The document is designed primarily to provide guidance on the direct clinical care of MSM but also makes reference to the design and delivery of services with the aim of supporting clinicians and commissioners in providing effective services. Methodology This document was produced in accordance with the guidance set out in the BASHH CEG's document 'Framework for guideline development and assessment' published in 2010 at http://www.bashh.org/guidelines and with reference to the Agree II instrument. Following the production of the updated framework in April 2015, the GRADE system for assessing evidence was adopted and the draft recommendations were regraded. Search strategy (see also Appendix 1) Ovid Medline 1946 to December 2014, Medline daily update, Embase 1974 to December 2014, Pubmed NeLH Guidelines Database, Cochrane library from 2000 to December 2014. Search language English only. The search for Section 3 was conducted on PubMed to December 2014. Priority was given to peer-reviewed papers published in scientific journals, although for many issues evidence includes conference abstracts listed on the Embase database. In addition, for 'Identification of problematic recreational drug and alcohol use' section and 'Sexual problems and dysfunctions in MSM' section, searches included PsycINFO. Methods Article titles and abstracts were reviewed and if relevant the full text article was obtained. Priority was given to randomised controlled trial and systematic review evidence, and recommendations made and graded on the basis of best available evidence. Piloting and feedback The first draft of the guideline was circulated to the writing group and to a small group of relevant experts, third sector partners and patient representatives who were invited to comment on the whole document and specifically on particular sections. The revised draft was reviewed by the CEG and then reviewed by the BASHH patient/public panel and posted on the BASHH website for public consultation. The final draft was piloted before publication. Guideline update The guidelines will be reviewed and revised in five years' time, 2022.
- Published
- 2018
- Full Text
- View/download PDF
13. Leprous osteitis presenting as bone cyst and erosions.
- Author
-
Dave S, Nori AV, Thappa DM, and Siddaraju N
- Subjects
- Adult, Bone Cysts diagnostic imaging, Bone Cysts microbiology, Bone Cysts pathology, Foot Ulcer pathology, Hand diagnostic imaging, Humans, Leprosy, Lepromatous microbiology, Leprosy, Lepromatous pathology, Male, Mycobacterium leprae isolation & purification, Osteitis microbiology, Osteitis pathology, Osteomyelitis diagnostic imaging, Osteomyelitis etiology, Osteomyelitis microbiology, Osteomyelitis pathology, Radiography, Bone Cysts etiology, Foot Ulcer etiology, Hand pathology, Leprosy, Lepromatous complications, Osteitis etiology, Toes pathology
- Abstract
A 30-year-old man presented to the Hansen outpatient department with swelling and ulceration of toes for 2 months and swelling of the right fifth and fourth fingers and the left second finger for 1 month. In addition to skin lesions of lepromatous leprosy (subpolar type), there was nontender, non-fluctuant swelling of the right fifth and fourth fingers and left second finger. Skin over the right fifth finger showed sinus-like openings with associated purulent discharge. He also had swelling and ulceration of second left toe. Slit-skin smear (SSS) showed a bacterial index of 6+ from the ear lobes and cutaneous nodules, 4+ from the patch, and 3+ from normal skin. Modified Ziehl-Neelsen staining of the discharge extruding from the sinuses on the right fifth finger also showed abundant acid-fast bacilli. Radiography of the hands and feet showed lytic lesions in the distal epimetaphyseal region o proximal phalanx of the right fifth finger and left second finger and erosion of distal end of proximal phalanges of both second toes. Histopathological examination of biopsy specimen from the patch (back) showed features of lepromatous leprosy, and Fite-Faraco stain for tissue acid-fast bacteria (AFB) was strongly positive. Fine-needle-aspiration cytology (FNAC) from the lytic lesion in the bone also showed predominantly foamy macrophages with strongly positive staining for AFB with a few interspersed lymphocytes, epithelioid cells and Langhans giant cells. On the basis of these features, a clinical diagnosis of subpolar lepromatous leprosy with leprous osteitis was made. In today's clinical era of improved case detection and prompt treatment with effective multidrug regimens, advanced bone changes are rarely encountered. We describe this case of lepromatous leprosy that developed cavitating lesions of the phalanges of the hand, seen on x-ray as well-defined bone cyst and erosions.
- Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.